Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of 9MW3811 in Healthy Participants
NCT05912049Phase 1Unknown
- Sponsor
- Mabwell
- Start
- Jul 2023
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing 9MW3811 Injection with Placebo (2 arms). Primary endpoint: Incidence of adverse events (AEs) at Day 113. Status: unknown.
02
Drugs
9MW3811
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05912049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05912049.